{"topic_id":"ade_oclacitinib_adverse_events","category":"ade","context":"---\ntopic_id: ade_oclacitinib\ncategory: ade\ntitle: \"FDA ADE reports for Oclacitinib — total reports, species & reaction breakdown\"\nlang: en\nsource: \"openFDA animalandveterinary/event.json (FDA CVM adverse event reports), pulled 2026-07-22\"\nsource_file: pdf-raw/ade/ade_active_ingredients_2026-07-22.json\ndate_parsed: 2026-07-22\ntokens_estimated: 200\nverification:\n  method: substring_match\n  claims: 17\n  passed: 17\n  date: 2026-07-22\n---\n\n# Oclacitinib — FDA Animal & Veterinary Adverse Event (ADE) Reports\n\nSource: openFDA `animalandveterinary/event.json`, the FDA Center for Veterinary Medicine (CVM) adverse event report database. Data pulled 2026-07-22. Counts are report-level: one report may list multiple reactions and multiple animals, so figures are not additive and do not imply causation. Oclacitinib is a veterinary active ingredient.\n\n## Total reports\nOclacitinib: 29980\n\n## Reports by species (top entries)\n- Dog 28319\n- Cat 434\n- Human 151\n- Horse 13\n- Lynx 2\n- Monkey 2\n\n## Top reported reactions (VEDDRA terms, top entries)\n- Lack of efficacy - NOS 3728\n- Vomiting 3422\n- INEFFECTIVE, ATOPY CONTROL 2705\n- Diarrhoea 2309\n- Lethargy (see also Central nervous system depression in 'Neurological') 2168\n- INEFFECTIVE, LOSS OF EFFECT 1807\n- Other abnormal test result NOS 1417\n- Elevated alanine aminotransferase (ALT) 1173\n- Seizure NOS 1125\n- Elevated serum alkaline phosphatase (SAP) 1056\n\n\"Lack of efficacy\" terms denote product-performance reports, not adverse reactions.\n\nSource JSON: `pdf-raw/ade/ade_active_ingredients_2026-07-22.json` (openFDA animalandveterinary/event.json, pulled 2026-07-22).\n","sources":[],"tokens_estimated":200,"generated_at":null,"tip":"Use /api/v1/topics to discover more topics. /api/v1/nutrient for precise single-point queries. /api/v1/cross_compare for 2-3 standard comparisons."}